BG106567A - Purine derivatives - Google Patents

Purine derivatives

Info

Publication number: BG106567A
Authority: BG; Bulgaria
Prior art keywords: compounds; purine derivatives; preparation; adenosine; solvates
Prior art date: 1999-10-14

Application number

BG106567A

Other languages

Bulgarian (bg)

English (en)

Inventor

Sandra MONAGHAN

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-14

Filing date

2002-04-02

Publication date

2002-12-29

2002-04-02 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2002-12-29 Publication of BG106567A publication Critical patent/BG106567A/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Immunology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Psychiatry (AREA)
Obesity (AREA)

BG106567A 1999-10-14 2002-04-02 Purine derivatives BG106567A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9924361.0A GB9924361D0 (en)	1999-10-14	1999-10-14	Purine derivatives
PCT/IB2000/001446 WO2001027131A1 (en)	1999-10-14	2000-10-06	Purine derivatives

Publications (1)

Publication Number	Publication Date
BG106567A true BG106567A (en)	2002-12-29

Family

ID=10862758

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106567A BG106567A (en)	1999-10-14	2002-04-02	Purine derivatives

Country Status (43)

Country	Link
US (1)	US6448236B1 (is)
EP (1)	EP1220862B1 (is)
JP (1)	JP3994008B2 (is)
KR (1)	KR20030022758A (is)
CN (1)	CN1166678C (is)
AP (1)	AP2002002480A0 (is)
AR (1)	AR026052A1 (is)
AT (1)	ATE321065T1 (is)
AU (1)	AU771531B2 (is)
BG (1)	BG106567A (is)
BR (1)	BR0014760A (is)
CA (1)	CA2387533C (is)
CO (1)	CO5261621A1 (is)
CR (1)	CR6607A (is)
CZ (1)	CZ20021179A3 (is)
DE (1)	DE60026861T2 (is)
EA (1)	EA004985B1 (is)
EC (1)	ECSP003713A (is)
EE (1)	EE200200194A (is)
ES (1)	ES2257317T3 (is)
GB (1)	GB9924361D0 (is)
GE (1)	GEP20043324B (is)
GT (2)	GT200000170A (is)
HK (1)	HK1047942B (is)
HR (1)	HRP20020325A2 (is)
HU (1)	HUP0203485A3 (is)
IL (1)	IL148331A0 (is)
IS (1)	IS6287A (is)
MA (1)	MA26829A1 (is)
MX (1)	MXPA02003750A (is)
MY (1)	MY141512A (is)
NO (1)	NO20021751L (is)
NZ (1)	NZ517294A (is)
OA (1)	OA12060A (is)
PA (1)	PA8503601A1 (is)
PE (1)	PE20010753A1 (is)
PL (1)	PL354880A1 (is)
SK (1)	SK4742002A3 (is)
SV (1)	SV2002000199A (is)
TN (1)	TNSN00203A1 (is)
TR (1)	TR200201001T2 (is)
WO (1)	WO2001027131A1 (is)
ZA (1)	ZA200202725B (is)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
GB0015727D0 (en) *	2000-06-27	2000-08-16	Pfizer Ltd	Purine derivatives
US6921753B2 (en)	2000-06-27	2005-07-26	Pfizer Inc	Purine derivatives
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US20050033044A1 (en) *	2003-05-19	2005-02-10	Bristol-Myers Squibb Pharma Company	Methods for preparing 2-alkynyladenosine derivatives
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US8012964B2 (en)	2004-03-26	2011-09-06	Dainippon Sumitomo Pharma Co., Ltd.	9-substituted 8-oxoadenine compound
TWI346109B (en)	2004-04-30	2011-08-01	Otsuka Pharma Co Ltd	4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
US7423144B2 (en) *	2004-05-26	2008-09-09	Inotek Pharmaceuticals Corporation	Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
BRPI0515506A (pt) *	2004-09-20	2008-07-29	Inotek Pharmaceuticals Corp	derivados de purina e métodos de uso dos mesmos
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US7910708B2 (en)	2005-10-21	2011-03-22	Novartis Ag	Anti-IL13 human antibodies
BRPI0619261A2 (pt) *	2005-11-30	2011-09-27	Inotek Pharmaceuticals Corp	derivados de purina e métodos de uso desses
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
ATE549337T1 (de) *	2006-04-21	2012-03-15	Novartis Ag	Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
WO2008004948A1 (en)	2006-07-05	2008-01-10	Astrazeneca Ab	8-oxoadenine derivatives acting as modulators of tlr7
KR20090073121A (ko)	2006-09-29	2009-07-02	노파르티스 아게	Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
KR20090075714A (ko)	2006-10-30	2009-07-08	노파르티스 아게	소염제로서의 헤테로시클릭 화합물
TW200831105A (en) *	2006-12-14	2008-08-01	Astrazeneca Ab	Novel compounds
WO2008107368A1 (en) *	2007-03-02	2008-09-12	Glaxo Group Limited	Purines as cysteine protease inhibitors
JP5329444B2 (ja) *	2007-03-19	2013-10-30	アストラゼネカ・アクチエボラーグ	Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
SI2132209T1 (sl) *	2007-03-19	2014-05-30	Astrazeneca Ab	Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7)
EP2138497A4 (en)	2007-03-20	2012-01-04	Dainippon Sumitomo Pharma Co	NEW ADENINE CONNECTION
AR065784A1 (es) *	2007-03-20	2009-07-01	Dainippon Sumitomo Pharma Co	Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2155743B1 (en) *	2007-05-08	2012-08-29	AstraZeneca AB	Imidazoquinolines with immuno-modulating properties
PE20091156A1 (es)	2007-12-17	2009-09-03	Astrazeneca Ab	Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
EP2231642B1 (en)	2008-01-11	2013-10-23	Novartis AG	Pyrimidines as kinase inhibitors
JPWO2009091031A1 (ja) *	2008-01-17	2011-05-26	大日本住友製薬株式会社	アデニン化合物の製造方法
WO2009091032A1 (ja)	2008-01-17	2009-07-23	Dainippon Sumitomo Pharma Co., Ltd.	アデニン化合物の製造方法
PL2391366T3 (pl)	2009-01-29	2013-04-30	Novartis Ag	Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
MY162604A (en)	2009-08-17	2017-06-30	Intellikine Llc	Heterocyclic compounds and uses thereof
MX2012002179A (es)	2009-08-20	2012-03-16	Novartis Ag	Compuestos heterociclicos de oxima.
EP2507237A1 (en) *	2009-12-03	2012-10-10	Dainippon Sumitomo Pharma Co., Ltd.	Imidazoquinolines which act via toll - like receptors (tlr)
LT2523669T (lt)	2010-01-11	2017-04-25	Inotek Pharmaceuticals Corporation	Akispūdžio mažinimo būdas, derinys ir rinkinys
AU2011230580A1 (en)	2010-03-26	2012-10-11	Inotek Pharmaceuticals Corporation	Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
WO2012080728A1 (en)	2010-12-16	2012-06-21	Astrazeneca Ab	Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
ES2627433T3 (es)	2010-12-17	2017-07-28	Sumitomo Dainippon Pharma Co., Ltd.	Derivados de purina
JP2014505088A (ja)	2011-02-10	2014-02-27	ノバルティスアーゲー	Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en)	2011-02-23	2016-08-10	Intellikine, LLC	Heterocyclic compounds and uses thereof
AU2012220572A1 (en)	2011-02-25	2013-08-29	Irm Llc	Compounds and compositions as trk inhibitors
UY34329A (es)	2011-09-15	2013-04-30	Novartis Ag	Compuestos de triazolopiridina
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
PL2807178T3 (pl)	2012-01-26	2017-12-29	Inotek Pharmaceuticals Corporation	Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
CN110507654A (zh)	2012-04-03	2019-11-29	诺华有限公司	有酪氨酸激酶抑制剂的组合产品和其应用
WO2014152723A1 (en)	2013-03-15	2014-09-25	Inotek Pharmaceuticals Corporation	Ophthalmic formulations
EP2968340A4 (en)	2013-03-15	2016-08-10	Intellikine Llc	COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en)	2013-12-03	2015-06-11	Novartis Ag	Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
KR20170036037A (ko)	2014-07-31	2017-03-31	노파르티스 아게	조합 요법
CN113194752A (zh)	2018-06-01	2021-07-30	康奈尔大学	Pi3k相关疾病或病症的组合疗法
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5536419A (en) *	1978-09-08	1980-03-14	Yamasa Shoyu Co Ltd	2-substituted adenosine derivative and its preparation
AU8276187A (en) *	1986-10-31	1988-05-25	Warner-Lambert Company	Selected n6-substituted adenosines having selective a2 binding activity
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5877180A (en) *	1994-07-11	1999-03-02	University Of Virginia Patent Foundation	Method for treating inflammatory diseases with A2a adenosine receptor agonists
GB9414193D0 (en)	1994-07-14	1994-08-31	Glaxo Group Ltd	Compounds
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
BR9914526A (pt) *	1998-10-16	2001-07-03	Pfizer	Derivados de adenina
GB9913932D0 (en)	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives

1999
- 1999-10-14 GB GBGB9924361.0A patent/GB9924361D0/en not_active Ceased
2000
- 2000-09-26 PA PA20008503601A patent/PA8503601A1/es unknown
- 2000-10-06 HK HK03100163.8A patent/HK1047942B/zh not_active IP Right Cessation
- 2000-10-06 NZ NZ517294A patent/NZ517294A/en unknown
- 2000-10-06 DE DE60026861T patent/DE60026861T2/de not_active Expired - Fee Related
- 2000-10-06 IL IL14833100A patent/IL148331A0/xx unknown
- 2000-10-06 AP APAP/P/2002/002480A patent/AP2002002480A0/en unknown
- 2000-10-06 EE EEP200200194A patent/EE200200194A/xx unknown
- 2000-10-06 GE GE4727A patent/GEP20043324B/en unknown
- 2000-10-06 SK SK474-2002A patent/SK4742002A3/sk unknown
- 2000-10-06 EP EP00962773A patent/EP1220862B1/en not_active Expired - Lifetime
- 2000-10-06 AT AT00962773T patent/ATE321065T1/de not_active IP Right Cessation
- 2000-10-06 CA CA002387533A patent/CA2387533C/en not_active Expired - Fee Related
- 2000-10-06 TR TR2002/01001T patent/TR200201001T2/xx unknown
- 2000-10-06 HR HR20020325A patent/HRP20020325A2/xx not_active Application Discontinuation
- 2000-10-06 BR BR0014760-5A patent/BR0014760A/pt not_active IP Right Cessation
- 2000-10-06 OA OA1200200103A patent/OA12060A/en unknown
- 2000-10-06 PL PL00354880A patent/PL354880A1/xx not_active Application Discontinuation
- 2000-10-06 JP JP2001530349A patent/JP3994008B2/ja not_active Expired - Fee Related
- 2000-10-06 ES ES00962773T patent/ES2257317T3/es not_active Expired - Lifetime
- 2000-10-06 CZ CZ20021179A patent/CZ20021179A3/cs unknown
- 2000-10-06 KR KR1020027004766A patent/KR20030022758A/ko not_active Abandoned
- 2000-10-06 AU AU74412/00A patent/AU771531B2/en not_active Ceased
- 2000-10-06 CN CNB008141762A patent/CN1166678C/zh not_active Expired - Fee Related
- 2000-10-06 HU HU0203485A patent/HUP0203485A3/hu unknown
- 2000-10-06 MX MXPA02003750A patent/MXPA02003750A/es active IP Right Grant
- 2000-10-06 WO PCT/IB2000/001446 patent/WO2001027131A1/en not_active Ceased
- 2000-10-06 EA EA200200360A patent/EA004985B1/ru not_active IP Right Cessation
- 2000-10-10 GT GT200000170A patent/GT200000170A/es unknown
- 2000-10-12 EC EC2000003713A patent/ECSP003713A/es unknown
- 2000-10-12 MY MYPI20004789A patent/MY141512A/en unknown
- 2000-10-12 GT GT200000173A patent/GT200000173A/es unknown
- 2000-10-12 CO CO00077983A patent/CO5261621A1/es not_active Application Discontinuation
- 2000-10-13 TN TNTNSN00203A patent/TNSN00203A1/fr unknown
- 2000-10-13 SV SV2000000199A patent/SV2002000199A/es unknown
- 2000-10-13 AR ARP000105422A patent/AR026052A1/es unknown
- 2000-10-13 PE PE2000001099A patent/PE20010753A1/es not_active Application Discontinuation
- 2000-10-16 US US09/688,497 patent/US6448236B1/en not_active Expired - Fee Related
2002
- 2002-02-26 IS IS6287A patent/IS6287A/is unknown
- 2002-03-11 CR CR6607A patent/CR6607A/es not_active Application Discontinuation
- 2002-04-02 BG BG106567A patent/BG106567A/xx unknown
- 2002-04-08 ZA ZA200202725A patent/ZA200202725B/en unknown
- 2002-04-09 MA MA26591A patent/MA26829A1/fr unknown
- 2002-04-12 NO NO20021751A patent/NO20021751L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EA004985B1 (ru)	2004-10-28
HK1047942B (zh)	2005-04-01
GEP20043324B (en)	2004-04-13
CO5261621A1 (es)	2003-03-31
AU7441200A (en)	2001-04-23
ES2257317T3 (es)	2006-08-01
NO20021751D0 (no)	2002-04-12
MA26829A1 (fr)	2004-12-20
JP2003511460A (ja)	2003-03-25
GB9924361D0 (en)	1999-12-15
DE60026861T2 (de)	2006-09-21
MY141512A (en)	2010-05-14
AU771531B2 (en)	2004-03-25
CA2387533C (en)	2007-03-13
NZ517294A (en)	2004-03-26
ECSP003713A (es)	2002-05-23
CN1166678C (zh)	2004-09-15
EP1220862B1 (en)	2006-03-22
NO20021751L (no)	2002-06-13
AP2002002480A0 (en)	2002-06-30
IL148331A0 (en)	2002-09-12
CA2387533A1 (en)	2001-04-19
US6448236B1 (en)	2002-09-10
KR20030022758A (ko)	2003-03-17
PE20010753A1 (es)	2001-07-17
PA8503601A1 (es)	2002-02-21
DE60026861D1 (de)	2006-05-11
CR6607A (es)	2003-11-25
PL354880A1 (en)	2004-03-22
EE200200194A (et)	2003-06-16
ATE321065T1 (de)	2006-04-15
HUP0203485A3 (en)	2005-02-28
EP1220862A1 (en)	2002-07-10
BR0014760A (pt)	2002-07-02
HRP20020325A2 (en)	2004-04-30
HUP0203485A2 (hu)	2003-03-28
WO2001027131A1 (en)	2001-04-19
CN1378551A (zh)	2002-11-06
HK1047942A1 (zh)	2003-03-14
SV2002000199A (es)	2002-02-05
GT200000173A (es)	2002-04-05
TR200201001T2 (tr)	2002-09-23
MXPA02003750A (es)	2003-10-14
AR026052A1 (es)	2002-12-26
EA200200360A1 (ru)	2002-10-31
JP3994008B2 (ja)	2007-10-17
SK4742002A3 (en)	2003-05-02
IS6287A (is)	2002-02-26
CZ20021179A3 (cs)	2003-04-16
TNSN00203A1 (fr)	2002-05-30
OA12060A (en)	2006-05-03
GT200000170A (es)	2002-04-03
ZA200202725B (en)	2003-04-08

Publication	Publication Date	Title
BG106289A (en)	2002-09-30	Purine derivatives
MY136242A (en)	2008-08-29	Purine derivatives
AP2002002480A0 (en)	2002-06-30	Purine derivatives.
AP2001002287A0 (en)	2001-12-31	Purine derivatives.
AP2002002598A0 (en)	2002-09-30	Purine derivatives.
CA2412564A1 (en)	2002-01-03	Purine derivatives
AU5879299A (en)	2000-05-08	Adenine derivatives
MXPA02012033A (es)	2003-04-25	Derivados de 2-aminocarbonil-9h-purina.
HRP20031003A2 (en)	2004-06-30	4'-substituted nukleosides
IL150986A0 (en)	2003-02-12	1,2,3,4,- tetrahydroisoquinoline derivatives
IL159880A0 (en)	2004-06-20	Arylsulfonyl derivatives with 5-ht6 receptor affinity
GEP20094697B (en)	2009-06-10	Condensed purine derivatives as a1 adenosine receptor antagonists
TW360652B (en)	1999-06-11	Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them
YU82302A (sh)	2005-11-28	Derivati 2-aminokarbonil-9h-purina